Business
Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®
LOS ANGELES, February 25, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the broadening of its NAD+ precursor intellectual property (IP) portfolio with the newly granted U.S. Patent No. 12,558,367, which covers the methods of use of nicotinamide riboside (NR) and derivatives in intravenous and injectable formulations.
About this update from Niagen Bioscience, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2250,"height":450,"url":"https://media.zenfs.com/en/business-wire.com/4b2dc2c94da5aa630e1d226fba1b5500"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.la21j37viLbgBDN5hxmnA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4b2dc2c94da5aa630e1d226fba1b5500","width":960,"height":192},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/NQeMgglTExiqoSA_oTarKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00ODA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/4b2dc2c94da5aa630e1d226fba1b5500","width":1200,"height":240}},"lazy":false},{"type":"text","content":"Patent strengthens Niagen Bioscience’s intellectual property moat in fast-growing NAD+-boosting IV and injectable delivery formats, supporting commercial expansion and deterring infringers","length":188,"tagName":"p","attribs":{}},{"type":"text","content":"LOS ANGELES, February 25, 2026--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the broadening of its NAD+ precursor intellectual property (IP) portfolio with the newly granted U.S. Patent No. 12,558,367, which covers the methods of use of nicotinamide riboside (NR) and derivatives in intravenous and injectable formulations.","length":462,"tagName":"p"},{"type":"text","content":"Rob Fried, CEO of Niagen Bioscience, commented, "This patent expands our intellectual property for our patented NR ingredient, Niagen®, into IV and injectable delivery formats. With expected protection through 2044, it supports Niagen’s exclusivity in delivering a superior IV and injectable product with significantly faster delivery and improved comfort for patients across our expanding U.S. clinic footprint."","length":423,"tagName":"p"},{"type":"text","content":"Under its Niagen Plus product portfolio, Niagen Bioscience developed a next-generation intravenous formulation of pharmaceutical-grade Niagen designed to support healthy aging and longevity at the cellular level. Compared to traditional NAD+ IV, the aqueous-based intravenous Niagen formulation supports faster infusions and elevates NAD+ levels higher without the severe ...